Akebia Therapeutics, Inc. (AKBA) Q2 FY26 Earnings Call

VOICE strengthens Vasio's commercial case, but the 2027 price reset and Auryxia erosion remain material offsets.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-05
Length37 minutes
EPS$-0.02
EPS consensus$-0.03
Revenue$49.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All AKBA earnings ยท Back to AKBA overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.